Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.

Xin Yi WongWee Joo ChngMohamed Ismail Abdul AzizKwong Ng

Published in: Expert review of pharmacoeconomics & outcomes research (2021)

At current prices, the addition of daratumumab to lenalidomide and dexamethasone does not represent cost-effective use of healthcare resources in Singapore.

Keyphrases

multiple myeloma
healthcare
high dose
low dose
acute lymphoblastic leukemia
diffuse large b cell lymphoma
health insurance
newly diagnosed